Mechanism of Ocrelizumab in B-Cell Depletion

How does ocrelizumab target CD20-positive B cells to drive B-cell depletion?

Ocrelizumab binds to CD20 on B cells and drives their depletion primarily through antibody-dependent cellular cytotoxicity mediated by monocytes via Fcγ receptor pathways, achieving rapid and sustained reduction of circulating B cells while also depleting CD20-positive T-cell subsets.

Abstract

Ocrelizumab is a humanized anti-CD20 monoclonal antibody that targets the same CD20 epitope as rituximab but achieves B-cell depletion primarily through antibody-dependent cellular cytotoxicity (ADCC) rather than complement-dependent cytotoxicity (CDC). The antibody was engineered with amino acid modifications to enhance binding to Fcγ receptor IIIa, resulting in two- to five-fold greater ADCC activity compared to rituximab. Monocytes serve as the dominant effector cells mediating B-cell depletion through FcγRI and FcγRIII-dependent pathways, achieving rapid onset within hours and near-complete depletion (>95%) of circulating B cells by week 2. However, depletion efficiency varies across anatomical compartments, with secondary lymphoid organs retaining resistant B-cell subpopulations and bone marrow showing the weakest reduction. Ocrelizumab also co-depletes CD20-positive T-cell subsets and novel dual-expressor lymphocytes expressing both T-cell and B-cell receptors.

B-cell recovery begins in bone marrow and spleen before appearing in blood, with median time to repletion of 72 weeks. The phenotype of reconstituting B cells varies by immunological context: in settings with ongoing antigen stimulation, recovery is characterized by expansion of differentiated, myelin-reactive B cells, whereas absence of stimulation favors naive B-cell reconstitution. Treatment induces secondary immunological changes including increased BAFF levels and decreased sTACI, which may enhance regulatory plasma cell development and contribute to therapeutic efficacy. The ADCC-predominant mechanism provides more sustained depletion than CDC-predominant antibodies while potentially offering better tolerability.

Methods

We analyzed 10 sources from an initial pool of 200, using 6 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.

Data extraction

We asked a large language model to extract details about:

• CD20 Targeting: Binding characteristics, binding affinity, antibody structure features, and comparisons to other anti-CD20 antibodies.

• Cytotoxic Mechanisms: Mechanisms by which ocrelizumab induces B-cell death, including quantitative comparisons of mechanism potency.

• Depletion Patterns: B-cell subpopulations targeted, compartments affected, degree of depletion, and factors influencing depletion efficiency.

• Depletion Kinetics: Timing and kinetics of B-cell depletion and recovery across anatomical compartments.

• Molecular Determinants: Features that influence ocrelizumab's mechanism of action and dosing regimen.

• Comparative Mechanisms: Comparisons of ocrelizumab to other anti-CD20 antibodies in terms of mechanism and efficacy.

Results

Characteristics of Included Studies

Mechanisms of CD20 Targeting and B-cell Depletion

CD20 Binding Characteristics

Ocrelizumab is a humanized anti-CD20 monoclonal antibody that binds to the same epitope on the large extracellular loop of CD20 as rituximab. The antibody is classified as a type I anti-CD20 agent capable of crosslinking CD20 tetramers. Enhanced binding to low-affinity variants of Fcγ receptor IIIa distinguishes ocrelizumab from rituximab, contributing to its enhanced effector function.

Cytotoxic Mechanisms

Ocrelizumab depletes B cells primarily through ADCC. It exhibits two- to five-fold greater ADCC activity compared to rituximab and lower CDC activity. B-cell depletion is completely dependent on effector cell Fc receptor expression, with monocytes serving as the dominant effector cells.

Patterns of B-cell Depletion

B-cell Subpopulations

Ocrelizumab targets CD20-positive B cells resulting in significant reductions across multiple B-cell subsets including naive, memory, and transitional B cells. Plasma cells, which lack CD20 expression, remain resistant to depletion.

Anatomical Compartments

B-cell depletion occurs across multiple anatomical compartments but with varying efficiency. In blood, depletion is nearly complete, whereas lymph nodes and CNS are less affected. The bone marrow shows the weakest reduction in B-cell numbers.

Kinetics of Depletion and Recovery

Depletion Timeline

The onset of B-cell depletion is rapid, occurring within 1 hour, with maximal depletion persisting through week 96 with regular infusions.

Recovery Patterns

B-cell recovery shows complex kinetics, with populations reappearing in bone marrow and spleen before blood. Phenotype of reconstituting B cells varies with ongoing antigen stimulation influencing differentiation.

Comparative Analysis with Other Anti-CD20 Antibodies

Mechanistic Distinctions

Ocrelizumab exhibits distinct mechanistic properties compared to other anti-CD20 antibodies, relying more heavily on ADCC than CDC.

Clinical Impact

Ocrelizumab achieves more complete and sustained B-cell depletion than rituximab, which may affect clinical efficacy and safety.

Secondary Effects on Immune Regulation

BAFF-APRIL System Modulation

Treatment induces changes in BAFF and decreases sTACI levels, which may have implications for regulatory cell development.

Broader Immunological Changes

B-cell depletion is associated with decreases in cytokine signaling pathways and upregulation of various metabolic pathways in immune cells.

Synthesis

The mechanism by which ocrelizumab drives B-cell depletion involves multiple coordinated processes that vary by context, anatomical location, and B-cell phenotype. The apparent heterogeneity in depletion efficiency and recovery patterns across different compartments can be explained by distinct microenvironmental factors.